Molecular Pathology v. Myriad Genetics: The Implications of the Supreme Court Decision - IIPLA

Molecular Pathology v. Myriad Genetics: The Implications of the Supreme Court Decision

Categories: IP COURSES
Wishlist Share
Share Course
Page Link
Share On Social Media

About Course

About the Course:

In Molecular Pathology v. Myriad Genetics, the Supreme Court held that isolated DNA is not patent eligible subject matter, but that cDNA may be patent eligible subject matter under certain circumstances. This webinar discusses the extent to which additional limitations will be placed on the patentability of biotechnology claims.

Among additional issues discussed during this webinar are:

  • How will the Myriad decision impact the “law of nature” exceptions?
  • What are some of the limitations to the Myriad decision?
  • According to the Myriad decision, what is the distinction between “invention” and “discovery”?
  • How does the Myriad decision differ from the Mayo decision?
  • Why is it that, because of the Myriad decision, the better targeted personal medicine becomes, the less patent-eligible it will become?
  • What are potential variations of post-Myriad legislation and how might such legislation affect life sciences patents?
  • What is the history of the Court of Appeals for the Federal Circuit?
  • What is the disposition of the newly-appointed Supreme Court justices towards patents?
  • What is the proclivity of the Supreme Court to rely on decisions from foreign jurisdictions?
  • How influential are Amicus Curiae briefs on Supreme Court justices?
  • To what extent should we review decisions relating to plant patents in divining the direction of life science patent decisions?

Course Leader: Gregory A. Castanias, Partner, Jones Day

Greg Castanias is an appellate and intellectual property litigator with extensive Supreme Court and Federal Circuit advocacy experience. He heads Jones Day’s Federal Circuit practice. Greg’s experience includes several arguments and appearances before the U.S. Supreme Court, as well as over 40 arguments and approximately 150 appearances before the Federal Circuit, including some of the most pathbreaking cases in recent years. He has also argued several cases before the other federal courts of appeals and in state supreme courts from Alaska to Connecticut.

Some of the Firm clients Greg has represented in recent years include Abbott, Apple, ARRIS, Chevron, DePuy Spine, DIRECTV, Eastman Chemical, Fenwal, Histogen, Huawei, IBM, Illumina, LabCorp, Limited Brands, MathWorks, Myriad Genetics, Pfizer, Procter & Gamble, SanDisk, SAP, SAS Institute, Sinochem, Tesoro, Transocean, and Visa.

Course Length: Approx. 1.0 hours

Show More

Student Ratings & Reviews

No Review Yet
No Review Yet

Want to receive push notifications for all major on-site activities?

Make Payment to IIPLA

  • ✓ Valid number ✕ Invalid number
  • Minimum Payment is $100. Please note that if the amount entered is less than $100, the card will be charged for $100 for service management and processing.
  • Enter the details of the payment including invoice number or any other reason of payment.
  • $0.00
  • American Express
    Supported Credit Cards: American Express, Discover, MasterCard, Visa, JCB, Maestro

Buy WLF Dubai Delegate Ticket

Oops! We could not locate your form.